Pricing

Mersana Therapeutics Inc (MRSN)

followers ยท
Sector: HEALTH CARE
Industry: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
CEO: Anna Protopapas
Employees: 150
Web site: mersana.com
840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139
617-498-0020
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Mersana Therapeutics, Inc. develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for ovarian cancer and NSCLC adenocarcinoma.
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available